CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
1 other identifier
observational
5,000
1 country
1
Brief Summary
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 25, 2022
CompletedFirst Submitted
Initial submission to the registry
February 16, 2023
CompletedFirst Posted
Study publicly available on registry
February 27, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2099
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2099
February 9, 2026
January 1, 2026
77.2 years
February 16, 2023
February 5, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Alopecia epidemiology, presentation, natural history, management, and outcomes
The major clinical outcomes include an assessment of the epidemiology of AA; to better understand the presentation, natural history, management and outcomes.
A minimum of 10 years from last patient enrolled
Secondary Outcomes (10)
Physician Reported - Skindex-16
every 6 months for 10 years
Physician Reported - Alopecia Areata Symptom Impact Scale (AASIS)
every 6 months for 10 years
Physician Reported - Dermatology Life Quality Index (DLQI)
every 6 months for 10 years
Physician Reported - Severity of Alopecia Tool (SALT)
every 6 months for 10 years
Physician Reported - Alopecia Areata-Investigator Global Assessment (AA-IGA)
every 6 months for 10 years
- +5 more secondary outcomes
Study Arms (1)
Alopecia Areata
Pts presenting to enrolling sites across the US are invited to enroll if eligible
Eligibility Criteria
Patients are enrolled in the AA Registry during regularly scheduled office visits. Selected dermatologists are invited to participate as investigators in the Registry.
You may qualify if:
- A subject must meet all the following criteria to participate in the registry:
- Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner.
- Is at least 18 years of age or older.
- Is willing to provide Personal Information.
- Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment.
You may not qualify if:
- Any of the following would exclude the subject from participating in the registry:
- Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note:
- Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CorEvitaslead
Study Sites (1)
CorEvitas, LLC
Waltham, Massachusetts, 02451, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 16, 2023
First Posted
February 27, 2023
Study Start
October 25, 2022
Primary Completion (Estimated)
December 31, 2099
Study Completion (Estimated)
December 31, 2099
Last Updated
February 9, 2026
Record last verified: 2026-01